We can provide GMP validation service that complies with SFDA, FDA, WHO and EU EMPA.Excellent registration team could help us easlily to register our products in different countries.If you and your customer are interested in some products or need CMO business service because of capacity limit, product cost limit or developing limit, plz feel free to contact us. 

Besides, we could discuss the possible FDF distribution business. Hope to get the chance to discuss deeply.

Hangzhou Jinlan Pharm-Drugs Technology Co., Limited  is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int’l Airport and Shanghai Pudong Int’l Airport, the transportation and production environment are excellent.

We have established well market channels both domestically and overseas. Now JINLAN PHARMA is authorized by some Chinese chemical factories as universal agency and international area agency. Our products are exported to more than 100 countries and enjoy a well reputation, including Europe, USA, South America, India, south-east Asia and so on. Such as Canada, Germany, Spain, Australia, Russia, UAE, Estonia, Indonesia, Egypt, Pakistan and so on. Our machines with Excellent quality, Competitive price, Good after-service, are highly welcomed by our customers. We are pleased to know you and hope to be good friend and cooperator with you for our products. I am sure you will be satisfied with us.

Based on the philosophy of “Human-orient, Technical first, Quality product and High efficiency, Fact and Innovation”, JINLAN PHARMA highly welcome friends from all over the world to cooperate and get co-development. 

Description

Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is available as Xenazine in the United States as an orphan drug. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off label," tetrabenazine was the first approved treatment for Huntington's disease in the U.S. The compound has been known since the 1950s.

Basic Info

Numbering system

Properties

Safety Info